TRAF2 and chronic myelogenous leukemia, BCR-ABL1 positive: For chronic myelogenous leukemia (CML), it has been reported that the TRAF2-interacting TNFRSF receptor CD27 stimulates the oncogenic Wnt-β-catenin-TNIK-TCF4 pathway, resulting in enhanced proliferation of leukemia stem cells and leukemia progression in a TRAF2-dependent manner [236].